The New Arthritis Revolution: Better Drugs, Lower Costs

Arthritis is changing. Treatments are improving. Prices are finally falling.

For generations, arthritis was treated almost as an unavoidable part of growing older. A person developed aching knees, stiff fingers or painful hips, and the standard advice was often some version of: take a pain reliever, slow down and learn to live with it.

That approach is beginning to change.

Arthritis medicine is entering a new era in which doctors can do more than temporarily cover up pain. Newer treatments can target specific sources of inflammation, slow joint damage and help some people remain active and independent longer. At the same time, biosimilar competition and Medicare drug-price negotiations are beginning to challenge the extraordinarily high prices of certain arthritis medications.

This does not mean arthritis has been cured. It does not mean every new drug is appropriate for every patient. It certainly does not mean seniors should believe advertisements promising to rebuild worn-out joints overnight.

But the direction is encouraging: better diagnosis, more precise treatment, more medication choices and growing pressure to make those treatments affordable.

That is the new arthritis revolution.

Arthritis Is Not One Disease

The first thing to understand is that “arthritis” is not a single medical condition. The term covers more than 100 joint-related diseases and conditions.

The two forms most familiar to older adults are osteoarthritis and rheumatoid arthritis, but they have different causes and often require very different treatments.

Osteoarthritis is the most common form. It develops as cartilage and other tissues within a joint gradually break down. It frequently affects the knees, hips, hands, neck and lower back. Symptoms can include pain, stiffness, swelling and reduced movement. The National Institute of Arthritis and Musculoskeletal and Skin Diseases describes osteoarthritis as a degenerative joint disease that becomes more common with age.

Rheumatoid arthritis, on the other hand, is an autoimmune disease. The immune system mistakenly attacks healthy joint tissue, producing inflammation that can damage cartilage and bone. Rheumatoid arthritis may also affect the eyes, lungs, heart, blood vessels and other parts of the body.

Other important forms include psoriatic arthritis, gout, lupus-related arthritis and ankylosing spondylitis.

Saying “I have arthritis” is a little like telling a mechanic, “My car is making a noise.” That is useful information, but it is not enough to identify the problem.

Before discussing the newest medication, patients should ask a more basic question:

What type of arthritis do I actually have?

A correct diagnosis determines whether the goal is to control inflammation, manage pain, slow joint destruction, reduce uric acid or address another cause entirely.

Treating the Disease Instead of Only the Pain

The first major arthritis revolution has been the move from merely relieving pain to modifying the disease itself.

Traditional pain relievers may reduce discomfort, but they do not necessarily stop inflammatory arthritis from damaging a joint. For conditions such as rheumatoid arthritis, doctors now commonly use disease-modifying antirheumatic drugs, known as DMARDs.

Common traditional DMARDs include:

These medications can reduce inflammation and help prevent permanent joint damage.

When traditional DMARDs are not sufficient, a rheumatologist may recommend a biologic medication or another targeted drug. According to the American College of Rheumatology, examples include adalimumab, etanercept, abatacept and tocilizumab, as well as targeted medications such as tofacitinib and upadacitinib.

These treatments interfere with specific immune-system processes responsible for inflammation. Some block tumor necrosis factor, usually called TNF. Others target interleukins, immune cells or particular enzymes.

Patients do not need to memorize all those scientific names. The important point is that arthritis treatment is becoming more precise.

Instead of giving every patient the same medication and hoping for the best, doctors have a growing selection of treatments that work in different ways. The American College of Rheumatology notes that treatment decisions can depend on disease severity, medication costs, potential side effects and a patient’s personal preferences.

Finding the right treatment can still require trial and error. A drug that works extremely well for one person may produce little improvement in another. But having more choices makes it increasingly possible to change direction when a treatment is not working.

This fits the larger philosophy behind The Science of Elderhood: Four Pillars for Thriving in the Second Half of Life: aging well is not about pretending our bodies never change. It is about recognizing those changes early and adapting intelligently.

Biosimilars Could Change the Cost of Treatment

Some biological arthritis medications have transformed care, but their prices have placed them beyond the comfortable reach of many patients.

Biologics are more complicated to produce than conventional pills because they are made using living cells or organisms. When the patent on a traditional medication expires, another manufacturer can usually produce an almost identical generic version. Biologics are too complex to copy in precisely the same way.

Instead, competing manufacturers produce biosimilars.

The Food and Drug Administration defines a biosimilar as a biological product that is highly similar to an already-approved reference product and has no clinically meaningful differences in safety, purity or potency.

A biosimilar is not an inferior imitation. It must meet FDA standards before it can be approved. The FDA says biosimilars have the same strength, dosage, potential benefits and potential side effects as their reference products.

Biosimilars are now available for biologic medications used to treat rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. The FDA reported in March 2026 that it had approved 82 biosimilars for conditions including rheumatoid arthritis, cancer, diabetes and osteoporosis.

The purpose of biosimilar competition is simple: give patients more choices and put downward pressure on prices.

But we should not oversell what that means.

A lower manufacturer price does not always produce an equally dramatic reduction in the amount a patient pays. Formularies, deductibles, coinsurance, rebates, pharmacies and insurance contracts all affect the final cost.

Prescription pricing in America can resemble a restaurant where the menu lists no prices—and the customer receives the bill three months after dinner.

Nevertheless, competition matters. When multiple manufacturers can compete for the same patients, the original drug company no longer controls the entire market.

This is part of a larger change explored in Yesterday’s $10,000 Drug Is Today’s $30 Generic. Medical breakthroughs are important, but their full value is not realized until ordinary people can afford them.

Medicare Negotiation Is Affecting Arthritis Drugs

Another important development is Medicare’s new authority to negotiate prices for certain high-cost prescription drugs.

The first negotiated prices took effect on January 1, 2026. Among the medications selected were Enbrel and Stelara, two expensive biologic drugs used for inflammatory conditions.

Enbrel may be prescribed for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Stelara is used for conditions including psoriatic arthritis and psoriasis.

CMS reported that Enbrel’s negotiated 2026 price represented a reduction of approximately 67% from its 2023 list price. Stelara’s negotiated price represented a reduction of about 66%.

Those percentages sound enormous, but they require an important explanation.

The negotiated price is not necessarily the amount an individual patient pays at the pharmacy. A beneficiary’s personal cost depends on the Medicare plan, deductible, coinsurance, formulary placement and other coverage rules.

Still, negotiated prices can reduce the underlying amount around which the Medicare payment system operates. CMS originally estimated that Medicare beneficiaries would collectively save approximately $1.5 billion in out-of-pocket expenses during 2026 across the first 10 negotiated medications.

This is not the end of expensive arthritis drugs. It is the beginning of a system in which manufacturers may face more pressure to justify those prices.

Osteoarthritis Still Needs Its Own Revolution

Most seniors with arthritis have osteoarthritis, and this is where we must be especially careful about exaggerated promises.

The biologic drugs used for rheumatoid arthritis are generally not treatments for ordinary osteoarthritis. Osteoarthritis involves the deterioration of cartilage and other joint structures rather than the same autoimmune process found in rheumatoid arthritis.

Researchers are investigating cartilage regeneration, anti-inflammatory pathways, gene therapies and drugs that could potentially slow or modify osteoarthritis. Some early laboratory findings are genuinely exciting.

But experimental research is not the same as an approved treatment.

At present, osteoarthritis treatment may include:

NIAMS reports that exercise can reduce osteoarthritis pain and stiffness while increasing flexibility, muscle strength and endurance.

Weight management can also reduce stress on weight-bearing joints. For someone with knee or hip osteoarthritis, even a moderate reduction in body weight may make movement easier.

This does not mean every painful joint can be fixed by losing weight or walking more. That simplistic advice can be insulting to people with serious joint damage.

It means movement, strength and appropriate weight management remain important parts of treatment—even as science searches for more powerful solutions.

The goal is not to become an Olympic athlete at age 80. The goal is to avoid allowing the body to become a piece of patio furniture.

Newer Does Not Automatically Mean Safer

Powerful medications can produce powerful benefits, but they can also produce serious side effects.

Because many biologics and targeted arthritis drugs suppress parts of the immune system, they may increase vulnerability to infections. Patients may need testing for tuberculosis or hepatitis before beginning treatment.

Some medications carry warnings involving:

That does not make the drugs “bad.” Untreated inflammatory arthritis also carries risks, including irreversible joint damage, disability and effects on other organs.

The real question is not whether a medication has risks. Almost every effective medication does.

The question is whether its potential benefit outweighs its risk for a particular patient.

That decision should consider age, heart health, infection history, kidney and liver function, other medications and the severity of the disease.

Patients should also be skeptical of online advertisements claiming that a supplement, injection or overseas treatment can regrow cartilage or eliminate arthritis permanently.

When the advertisement includes a mysterious doctor, dramatic before-and-after pictures and a countdown clock telling you to order within seven minutes, keep your credit card in your pocket.

Real medical advances undergo testing. Miracle marketing usually undergoes video editing.

Five Questions Every Arthritis Patient Should Ask

Older adults can become more informed participants in their care by asking five practical questions:

1. What type of arthritis do I have?

Do not assume all joint pain is ordinary aging. Persistent swelling, warmth, prolonged morning stiffness or pain affecting several joints may require evaluation by a rheumatologist.

2. Is my treatment controlling the disease or only reducing pain?

For inflammatory arthritis, controlling the disease early may help prevent permanent damage.

3. Is a biosimilar available?

Ask whether an FDA-approved biosimilar could provide the same therapeutic benefit with lower cost-sharing.

4. Is the drug covered under Medicare Part B or Part D?

Some medications administered in a medical office may be covered differently from self-administered drugs obtained through a pharmacy.

5. What will my total annual cost be?

Do not look only at one copayment. Consider premiums, deductibles, coinsurance, pharmacy networks and the medication’s formulary tier.

A drug that appears affordable in January can become painfully expensive by July.

The Purpose Is Independence

The arthritis revolution is not one miracle drug.

It is the combination of earlier diagnosis, disease-modifying treatment, targeted medicine, biosimilar competition, price negotiation and a better understanding of how movement protects function.

Progress will not arrive evenly. Some medications will remain expensive. Some treatments will fail. Osteoarthritis still needs better disease-changing therapies.

But the old message—“You are getting older, so learn to live with the pain”—is becoming outdated.

Pain should not automatically be accepted as the admission price for growing older.

Ask questions. Get the correct diagnosis. Review your medication options. Compare the costs. Keep moving in every safe way possible.

As we discuss in You’re Not Getting Old—You’re Entering Elderhood, the second half of life should not be defined solely by what the body can no longer do. It should also be shaped by the treatments, knowledge and adaptations that allow us to continue participating in life.

The purpose of arthritis treatment is not simply to produce a better X-ray.

It is to help you get out of the chair, walk through your neighborhood, prepare your own meals, visit your family and remain in control of your daily life.

Better medicine matters.

Affordable medicine matters.

But your independence matters most.

This article is for educational purposes and is not a substitute for personal medical advice. Arthritis medications should not be started, stopped or changed without consulting a qualified healthcare professional.

Leave a Reply

Your email address will not be published. Required fields are marked *